Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six research firms that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $5.50.

Several analysts have issued reports on the company. StockNews.com cut Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday, December 24th. Wells Fargo & Company dropped their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an "equal weight" rating on the stock in a research report on Tuesday. Truist Financial raised shares of Sangamo Therapeutics from a "hold" rating to a "buy" rating and set a $7.00 price objective for the company in a report on Friday, December 13th. Jefferies Financial Group dropped their target price on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a "buy" rating on the stock in a report on Tuesday. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a report on Thursday, December 19th.

Sangamo Therapeutics Trading Down 56.4 %

SGMO stock traded down $1.32 during midday trading on Tuesday, hitting $1.02. 44,415,211 shares of the company's stock were exchanged, compared to its average volume of 7,095,709. The stock has a market capitalization of $212.82 million, a price-to-earnings ratio of -1.36 and a beta of 1.15. The firm has a 50 day moving average price of $2.16 and a 200-day moving average price of $1.22. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.07. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The company had revenue of $49.41 million during the quarter, compared to analyst estimates of $26.55 million. During the same period last year, the business earned ($0.34) EPS. On average, sell-side analysts forecast that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

Large investors have recently made changes to their positions in the business. Renaissance Technologies LLC grew its position in Sangamo Therapeutics by 58.8% during the second quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company's stock valued at $1,479,000 after purchasing an additional 1,528,600 shares in the last quarter. Marshall Wace LLP grew its holdings in shares of Sangamo Therapeutics by 56.3% during the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company's stock valued at $207,000 after acquiring an additional 207,476 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Sangamo Therapeutics in the second quarter worth $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Sangamo Therapeutics in the second quarter worth $89,000. Finally, Vontobel Holding Ltd. raised its holdings in shares of Sangamo Therapeutics by 412.3% during the third quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company's stock worth $259,000 after acquiring an additional 241,440 shares in the last quarter. Institutional investors and hedge funds own 56.93% of the company's stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.